3.4220
+0.0020
+(0.06%)
As of 9:50:56 AM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 3 | 3 |
| Avg. Estimate | 0 | 0 | -1.15 | -0.95 |
| Low Estimate | 0 | 0 | -1.19 | -1.3 |
| High Estimate | 0 | 0 | -1.1 | -0.35 |
| Year Ago EPS | -- | -- | -1.08 | -1.15 |
Revenue Estimate
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 5 | 5 |
| Avg. Estimate | -- | -- | 17.48M | 31.68M |
| Low Estimate | -- | -- | 12.6M | 8M |
| High Estimate | -- | -- | 20.9M | 55.3M |
| Year Ago Sales | -- | -- | 36.21M | 17.48M |
| Sales Growth (year/est) | -- | -- | -51.71% | 81.19% |
EPS Trend
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -1.15 | -0.95 |
| 7 Days Ago | 0 | 0 | -1.17 | -0.77 |
| 30 Days Ago | 0 | 0 | -1.17 | -0.77 |
| 60 Days Ago | 0 | 0 | -1.17 | -0.77 |
| 90 Days Ago | 0 | 0 | -1.17 | -0.77 |
EPS Revisions
| Currency in USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | 2 | 1 |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NBTX | -- | -- | -6.05% | 17.05% |
| S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Upgrades & Downgrades
| Initiated | Guggenheim: Buy | 8/28/2024 |
| Initiated | Leerink Partners: Outperform | 12/8/2023 |
| Initiated | Evercore ISI Group: Outperform | 1/6/2021 |
Related Tickers
IPHA Innate Pharma S.A.
1.8200
+5.81%
IVA Inventiva S.A.
2.2395
-3.88%
GNFT Genfit S.A.
3.6117
-0.78%
VALN Valneva SE
4.8300
-1.83%
XLO Xilio Therapeutics, Inc.
0.7549
-7.95%
PPCB Propanc Biopharma, Inc.
0.0003
+50.00%
REPL Replimune Group, Inc.
13.59
0.00%
VLA.PA Valneva SE
2.2760
+0.18%
SYRE Spyre Therapeutics, Inc.
22.28
+3.14%
OPT Opthea Limited
4.9600
+1.43%